Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(S)-(-)-5-Fluorowillardiine
Description: Very potent AMPA agonist
Chemical Name: (S)-(-)-α-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)pyridinepropanoic acid
Purity: ≥98% (HPLC)
Biological Activity for (S)-(-)-5-Fluorowillardiine
A more potent and selective AMPA receptor agonist (at hGluR1 and hGluR2) than AMPA itself (Ki = 14.7, 25.1, and 1820 nM for hGluR1, hGluR2 and hGluR5 respectively).
Technical Data for (S)-(-)-5-Fluorowillardiine
| M. Wt | 217.16 |
| Formula | C7H8FN3O4 |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 140187-23-1 |
| Smiles | O=C(C(F)=CN1C[C@@](N)([H])C(O)=O)NC1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for (S)-(-)-5-Fluorowillardiine
References for (S)-(-)-5-Fluorowillardiine
References are publications that support the biological activity of the product.
Hawkins et al (1995) Binding of the new radioligand (S)-[3H]-AMPA to rat brain synaptic membranes: effects of a series of structural analogues of the non-NMDA receptor agonist willardine. Neuropharmacology 34 405 PMID: 7566471
Jane et al (1997) Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J.Med.Chem. 40 3645 PMID: 9357531
Patneau et al (1992) Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J.Neurosci. 12 595 PMID: 1371315
Wong et al (1994) Willardiines differentiate agonist binding sites for kainate-versus AMPA-preferring glutamate receptors in DRG and hippocampal neurones. J.Neurosci. 14 3881 PMID: 7515954
View Related Products by Target
View Related Products by Product Action
Keywords: (S)-(-)-5-Fluorowillardiine, (S)-(-)-5-Fluorowillardiine supplier, potent, selective, AMPA, agonists, Glutamate, Receptors, iGluR, Ionotropic, 0306, Tocris Bioscience
Citations for (S)-(-)-5-Fluorowillardiine
Citations are publications that use Tocris products.
Currently there are no citations for (S)-(-)-5-Fluorowillardiine.
Reviews for (S)-(-)-5-Fluorowillardiine
There are currently no reviews for this product. Be the first to review (S)-(-)-5-Fluorowillardiine and earn rewards!
Have you used (S)-(-)-5-Fluorowillardiine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.